Taysha Gene Therapies Inc. (TSHA) News
Filter TSHA News Items
TSHA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TSHA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest TSHA News From Around the Web
Below are the latest news stories about TAYSHA GENE THERAPIES INC that investors may wish to consider to help them evaluate TSHA as an investment opportunity.
Acelyrin Leads The Charge With 2 Other US Penny StocksAs the U.S. stock market rebounds from a five-session losing streak, led by a rally in major technology companies, investors are keenly observing opportunities across various sectors. Penny stocks, while often seen as relics of past trading eras, continue to offer intriguing prospects for growth and value discovery. These stocks typically represent smaller or newer companies that can deliver significant returns when supported by strong financials and sound fundamentals. |
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on January 2, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 311,000 shares of the Company's common stock in connection with th |
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsTaysha Gene Therapies ( NASDAQ:TSHA ) Third Quarter 2024 Results Key Financial Results Net loss: US$25.5m (loss... |
Q3 2024 Taysha Gene Therapies Inc Earnings CallQ3 2024 Taysha Gene Therapies Inc Earnings Call |
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ...Despite a net loss, Taysha Gene Therapies Inc (TSHA) shows promising advancements in Rett syndrome treatment and maintains a strong cash position. |
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue EstimatesTaysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -12.50% and 4.54%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateHigh dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two (high dose) across both REVEAL trials; eight patients dosed to date (low dose=4, high dose=4) Advanced discussions with the FDA on trial design, endpoints and potential use of established natural history dataset for Part B of REVEAL trials, and aligned on a meeting cadence to expedite the development pl |
US Penny Stocks To Watch In November 2024As the U.S. stock market reaches record highs, fueled by a post-election rally and optimism surrounding interest rate cuts, investors are exploring various opportunities to capitalize on this momentum. Penny stocks, though often overlooked and considered a relic of past market days, remain an intriguing investment area for those seeking potential growth in smaller or lesser-known companies. By focusing on penny stocks with strong financial health and clear growth trajectories, investors might... |
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2024, and host a corporate update conference call and webcast on Wednesday, November 13, 2024, at 4:30 PM Eastern Time. Conference Call D |
Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT CongressData from an analysis of five NHP studies showed lumbar IT administration led to widespread and consistent biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions IT and ICM administration achieved comparable biodistribution across brain and spinal cord regions in NHPs Findings from the analysis reaffirm the clinical potential of IT administration as an effective, safe and minimally invasive approach to deliver AAV-based gene therapies designed to treat CNS diseases in |